AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3542851 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidometacin (600 mg rectal)
Number of subjects: 20
Study 3542851 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidometacin (capsules)
Number of subjects: 20
Study 3542851 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidometacin (suppositories)
Number of subjects: 20
Study 30417857 — intervention group
Group type: EXPERIMENTAL
Intervention: HFS patients
Number of subjects: 86
Study 30417857 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 86
Study 26778459 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI) and diffusion tensor imaging (DTI)
Number of subjects: 64
Study 24865394 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based recreational football, details on dosage and duration not available
Number of subjects: 0
Study 22609108 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m(2) and nedaplatin 80 mg/m(2) intravenously on day 1 every 28 days
Number of subjects: 50
Study 20595308 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized electronic alert requiring affirmative response
Number of subjects: 1963
Study 20595308 — intervention group
Group type: COMPARATOR
Intervention: Commercially available passive alert
Number of subjects: 1963
Study 18540731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Program (CRP)
Number of subjects: 161
Study 18716003 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 60
Study 18716003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15957718 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow sevoflurane (1 litre/min, n=9)
Number of subjects: 25
Study 15957718 — intervention group
Group type: COMPARATOR
Intervention: High-flow sevoflurane (5 litre/min, n=7)
Number of subjects: 25
Study 15957718 — intervention group
Group type: COMPARATOR
Intervention: Low-flow isoflurane (1 litre/min, n=9)
Number of subjects: 25
Study 11179983 — intervention group
Group type: EXPERIMENTAL
Intervention: Low M (omeprazole 20 mg twice daily, amoxycillin 1,000 mg twice daily, metronidazole 400 mg twice daily)
Number of subjects: 394
Study 11179983 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium M (omeprazole 40 mg once daily, amoxycillin 500 mg three times daily, metronidazole 400 mg three times daily)
Number of subjects: 394
Study 11179983 — intervention group
Group type: EXPERIMENTAL
Intervention: High M (omeprazole 20 mg twice daily, amoxycillin 1,000 mg twice daily, metronidazole 800 mg twice daily)
Number of subjects: 394
Study 11179983 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole susceptible strains
Number of subjects: 394
Study 11179983 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole resistant strains
Number of subjects: 394
Study 11179983 — intervention group
Group type: EXPERIMENTAL
Intervention: Low M (susceptible/resistant)
Number of subjects: 394
Study 11179983 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium M (susceptible/resistant)
Number of subjects: 394
Study 11179983 — intervention group
Group type: EXPERIMENTAL
Intervention: High M (susceptible/resistant)
Number of subjects: 394
Study 9268976 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1000
Study 9268976 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1000
Study 8471402 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine dihydrochloride 10 mg kg‐1 body weight by intravenous infusion over 1 h
Number of subjects: 8
Study 8471402 — intervention group
Group type: COMPARATOR
Intervention: Quinine 10 mg kg‐1 body weight by intravenous infusion over 1 h
Number of subjects: 8
Study 2869795 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 8
Study 2869795 — intervention group
Group type: COMPARATOR
Intervention: Loprazolam (1 mg)
Number of subjects: 8
Study 30944068 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Coated Balloon (DCB; coated with paclitaxel)
Number of subjects: 60
Study 30944068 — intervention group
Group type: COMPARATOR
Intervention: Standard Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 60
Study 30203771 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0
Study 30203771 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0
Study 26991622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D)
Number of subjects: 90
Study 26991622 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 90
Study 26991622 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (Group E)
Number of subjects: 90
Study 24805894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Symptom Management and Rehabilitation Therapy (CogSMART)
Number of subjects: 0
Study 24805894 — intervention group
Group type: COMPARATOR
Intervention: Enhanced supported employment (control)
Number of subjects: 0
Study 22721596 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 1.2 mg/kg/day
Number of subjects: 97
Study 22721596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 19580719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow AS (defined as stroke volume index <22 ml/m²)
Number of subjects: 1591
Study 19580719 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing LV global load
Number of subjects: 1591
Study 19580719 — intervention group
Group type: EXPERIMENTAL
Intervention: LV global load
Number of subjects: 1591
Study 19580719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection Fraction (EF)
Number of subjects: 1591
Study 17502568 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting with self‐expanding nitinol stents
Number of subjects: 104
Study 14692904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate intervention: Postal dissemination of the guideline supported by interactive, accredited workshops, and dedicated, structured protocol documents.
Number of subjects: 1133
Study 14692904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention: Intermediate intervention plus a nurse specialist who supported and educated practices in the establishment of epilepsy review clinics.
Number of subjects: 1133
Study 14692904 — intervention group
Group type: COMPARATOR
Intervention: Control: Postal dissemination of a nationally developed clinical guideline.
Number of subjects: 1133
Study 11668354 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis reported in RCT
Number of subjects: 32
Study 11668354 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodological aspects of SA reporting
Number of subjects: 32
Study 11668354 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of whether SA preceded/followed analysis
Number of subjects: 32
Study 11668354 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reporting of methodological aspects by journals
Number of subjects: 32
Study 11668354 — intervention group
Group type: EXPERIMENTAL
Intervention: Current reporting of SA in RCT
Number of subjects: 32
Study 9480993 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at doses of 5, 20, or 80 ppm
Number of subjects: 155
Study 9480993 — intervention group
Group type: COMPARATOR
Intervention: Control (0 ppm)
Number of subjects: 155
Study 8092502 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial tonometry
Number of subjects: 17
Study 8092502 — intervention group
Group type: COMPARATOR
Intervention: Oscillometry
Number of subjects: 17
Study 8092502 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial tonometry (after correction for calibration error)
Number of subjects: 17
Study 2963048 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 2963048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31037994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg daily
Number of subjects: 80
Study 31037994 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg daily
Number of subjects: 80
Study 30056389 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine aspirin 75 mg from 11 until 36 weeks
Number of subjects: 546
Study 30056389 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 546
Study 30056389 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening test indicated aspirin
Number of subjects: 546
Study 26830505 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption (non-skipper)
Number of subjects: 832
Study 26830505 — intervention group
Group type: COMPARATOR
Intervention: Breakfast skippers
Number of subjects: 832
Study 25661416 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 15
Study 25661416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 24044387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel
Number of subjects: 140
Study 24044387 — intervention group
Group type: COMPARATOR
Intervention: Proparacaine 0.5% eye drops
Number of subjects: 140
Study 20050764 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg/night
Number of subjects: 45
Study 20050764 — intervention group
Group type: COMPARATOR
Intervention: Low-dose transdermal estradiol 25 microg/day
Number of subjects: 45
Study 18218061 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based dietary counselling
Number of subjects: 43
Study 18218061 — intervention group
Group type: COMPARATOR
Intervention: Standardized, written nutritional information
Number of subjects: 43
Study 16303296 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 8
Study 16303296 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 8
Study 16303296 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB) with AE
Number of subjects: 8
Study 16303296 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB) without AE
Number of subjects: 8
Study 16303296 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB) with AE using PSV
Number of subjects: 8
Study 16303296 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB) with AE using PAV
Number of subjects: 8
Study 11960591 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 11960591 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 11960591 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms
Number of subjects: 0
Study 10407218 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5mg)
Number of subjects: 7
Study 10407218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7555484 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol (5 mg, twice a day for 12 weeks)
Number of subjects: 29
Study 7555484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2129189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (2 g intravenous, single dose 30 minutes before the operation)
Number of subjects: 78
Study 2129189 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 78
Study 7293522 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren 100 mg suppositories
Number of subjects: 0
Study 7293522 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprosyn 500 mg suppositories
Number of subjects: 0
Study 7293522 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprosyn tablets
Number of subjects: 0
Study 31535199 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rectal irrigation (group A)
Number of subjects: 122
Study 31535199 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (group C)
Number of subjects: 122
Study 28731600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable (F&V) concentrate
Number of subjects: 13
Study 28731600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 26593941 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of C. forskohlii extract, twice daily for 12 weeks
Number of subjects: 30
Study 26593941 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 12 weeks
Number of subjects: 30
Study 23352776 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 261
Study 23352776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 21352079 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day) plus Telmisartan (80 mg/day)
Number of subjects: 151
Study 21352079 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day) plus Irbesartan (300 mg/day)
Number of subjects: 151
Study 21352079 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day) plus Olmesartan (20 mg/day)
Number of subjects: 151
Study 19181476 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 0
Study 17632075 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical rumination
Number of subjects: 0
Study 17632075 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential rumination
Number of subjects: 0
Study 17632075 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 15042114 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan monotherapy (600-1200 mg/day)
Number of subjects: 283
Study 15042114 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan monotherapy
Number of subjects: 283
Study 15042114 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan + HCTZ (12.5 mg)
Number of subjects: 283
Study 15042114 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan + HCTZ
Number of subjects: 283
Study 15042114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 11504275 — intervention group
Group type: EXPERIMENTAL
Intervention: AP1903 0.01 mg/kg
Number of subjects: 28
Study 11504275 — intervention group
Group type: EXPERIMENTAL
Intervention: AP1903 0.05 mg/kg
Number of subjects: 28
Study 11504275 — intervention group
Group type: EXPERIMENTAL
Intervention: AP1903 0.1 mg/kg
Number of subjects: 28
Study 11504275 — intervention group
Group type: EXPERIMENTAL
Intervention: AP1903 0.5 mg/kg
Number of subjects: 28
Study 11504275 — intervention group
Group type: EXPERIMENTAL
Intervention: AP1903 1.0 mg/kg
Number of subjects: 28
Study 11504275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11504275 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 28
Study 9360205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration followed by Lactobacillus casei strain GG
Number of subjects: 100
Study 9360205 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration
Number of subjects: 100
Study 8285751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG 10(8) colony forming units twice a day for two weeks
Number of subjects: 20
Study 8285751 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 8285751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 20
Study 3556374 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine 7.5 micrograms/kg i.v.
Number of subjects: 7
Study 3556374 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 2.5 micrograms/kg i.v.
Number of subjects: 7
Study 3556374 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 31778277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (lifestyle intervention plus supervised exercise 3 sessions/week)
Number of subjects: 102
Study 31778277 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (family-based lifestyle and psycho-educational program)
Number of subjects: 102
Study 31778277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 102
Study 31778277 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 102
Study 31058615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching + 10% green tea
Number of subjects: 120
Study 31058615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching + 5% proanthocyanidins
Number of subjects: 120
Study 31058615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching + 10% alpha-tocopherol
Number of subjects: 120
Study 31058615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching + 10% sodium ascorbate
Number of subjects: 120
Study 31058615 — intervention group
Group type: COMPARATOR
Intervention: Negative control - no bleaching treatment
Number of subjects: 120
Study 31058615 — intervention group
Group type: COMPARATOR
Intervention: Positive control - bleaching
Number of subjects: 120
Study 29098841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanbitang recipe (TCM group)
Number of subjects: 168
Study 29098841 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate tablets (chemical medicine group)
Number of subjects: 168
Study 29098841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanbitang recipe and methotrexate tablets (TCM combined with chemical medicine group)
Number of subjects: 168
Study 25929919 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide (60 mg/m²/d on days 1‐10, followed by 11 days of rest)
Number of subjects: 75
Study 25929919 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 75
Study 23073721 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalization of motor experience
Number of subjects: 80
Study 23073721 — intervention group
Group type: COMPARATOR
Intervention: Irrelevant verbal task
Number of subjects: 80
Study 21557207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate (SSH) administered intravenously for 7 days
Number of subjects: 31
Study 19943787 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination schedule
Number of subjects: 26
Study 19943787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17034904 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching strategy including calculation assignments and medication calculation classes
Number of subjects: 54
Study 17034904 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous sophomore class)
Number of subjects: 54
Study 17034904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 54
Study 15346657 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole treatment
Number of subjects: 49
Study 10708052 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (zidovudine + lamivudine + ritonavir)
Number of subjects: 42
Study 10708052 — intervention group
Group type: COMPARATOR
Intervention: Double therapy (zidovudine + lamivudine)
Number of subjects: 42
Study 10708052 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 42
Study 9100591 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 0
Study 9100591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8403956 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nebulization of albuterol (0.3 mg/kg/hr)
Number of subjects: 17
Study 8403956 — intervention group
Group type: COMPARATOR
Intervention: Intermittent nebulization of albuterol (0.3 mg/kg over 20 mins every hour)
Number of subjects: 17
Study 8403956 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nebulization of albuterol
Number of subjects: 17
Study 8403956 — intervention group
Group type: COMPARATOR
Intervention: Intermittent nebulization of albuterol
Number of subjects: 17
Study 3511936 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily theophylline
Number of subjects: 15
Study 3358886 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 9
Study 3358886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30231787 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing sugar-free gum 2 hours after recovery for at least half an hour and at 2-hour intervals during daytime
Number of subjects: 372
Study 30231787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluids 6 hours postoperatively
Number of subjects: 372
Study 30231787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 372
Study 30937940 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg oral dose
Number of subjects: 0
Study 28375647 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 μg/62.5 μg/25 μg; ELLIPTA inhaler)
Number of subjects: 1810
Study 28375647 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily ICS/LABA therapy (budesonide/formoterol 400 μg/12 μg; Turbuhaler)
Number of subjects: 1810
Study 28375647 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol)
Number of subjects: 1810
Study 28375647 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily ICS/LABA therapy (budesonide/formoterol)
Number of subjects: 1810
Study 25816336 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional abuse from a current partner
Number of subjects: 103
Study 25816336 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 103
Study 25816336 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional abuse at baseline or prior to the first HIV+ test
Number of subjects: 103
Study 23265918 — intervention group
Group type: EXPERIMENTAL
Intervention: eSMART-MH (avatar-based depression self-management intervention)
Number of subjects: 0
Study 23265918 — intervention group
Group type: COMPARATOR
Intervention: Attention-control condition
Number of subjects: 0
Study 21537720 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 150
Study 21537720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 150
Study 21537720 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol plus promethazine
Number of subjects: 150